Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies.

Carfilzomib has a favorable benefit-risk profile in MM; adopting proactive practices can assist in the prevention, early detection, and management of carfilzomib-associated cardiovascular events, which may allow for continuation of therapy with this effective agent.